Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future ...

In Shareholder Representative Services LLC v. Alexion Pharmaceuticals, Inc., the Delaware Court of Chancery addressed an earnout dispute, holding ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have ...

The new board member appointments include: A new independent director: George Llado, the former Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc. George has more ...

Sticks and stones may break my bones, but words will never hurt me.” While this mantra may help bruised egos on ...

Mr. Tanguler brings over 25 years of senior leadership experience across notable organizations including Alnylam, Alexion Pharmaceuticals, Inc., and Pfizer Inc. Lexeo expects to provide an overview of ...

Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.